714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Polypepi1018 Colorectal Cancer	Mayo Clinic	P1/2	CCC (52)
Sulfasalazine Colorectal Cancer	Tanta University	P3	CCC (52)
Talazoparib Colorectal Cancer	Oslo University Hospital	P2	CCC (52)
Vemurafenib Colorectal Cancer	Shanghai Kechow Pharma, Inc.	P3	CCC (52)
Zimberelimab Colorectal Cancer	Taiho Pharmaceutical Co., Ltd.	P1/2	CCC (52)
Ziv-Aflibercept Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (52)
Abemaciclib Colorectal Cancer	National Cancer Institute (NCI)	P1/2	CCC (51)
Ctx-009 Colorectal Cancer	Compass Therapeutics	P2	CCC (51)
Dasatinib Colorectal Cancer	Oslo University Hospital	P2	CCC (51)
hlx43 Colorectal Cancer	Shanghai Henlius Biotech	P2	CCC (51)
jyp0015 Colorectal Cancer	Guangzhou JOYO Pharma Co., Ltd	P2	CCC (51)
Lubiprostone Colorectal Cancer	Sun Yat-sen University	P2	CCC (51)
Neurotropin Colorectal Cancer	Sun Yat-sen University	P3	CCC (51)
Pertuzumab Colorectal Cancer	Fudan University	P2	CCC (51)
Tiragolumab Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (51)
vv1 Colorectal Cancer	Vyriad, Inc.	P2	CCC (51)
Autogene Cevumeran Colorectal Cancer	BioNTech SE	P2	CCC (50)
BMS986310 Colorectal Cancer	Ono Pharmaceutical Co., Ltd.	P2	CCC (50)
Datopotamab Deruxtecan Colorectal Cancer	AstraZeneca	P2	CCC (50)
Ezabenlimab Colorectal Cancer	Institut Bergonié	P2	CCC (50)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Colorectal Cancer	Kineta Inc.	P1/2	CCC (50)
im96 car-t cells Colorectal Cancer	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1	CCC (50)
Inavolisib Colorectal Cancer	Hoffmann-La Roche	P2	CCC (50)
Kras Tcr-Transduced Pbl Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (50)
Mebendazole Colorectal Cancer	Sherief Abd-Elsalam	P3	CCC (50)
NKG2D CAR-NK Colorectal Cancer	Zhejiang University	P1	CCC (50)
Pirfenidone Colorectal Cancer	Guoxiang Cai	P2	CCC (50)
Prednisolone Colorectal Cancer	AstraZeneca	P2	CCC (50)
Riluzole Colorectal Cancer	University of California, Irvine	P2	CCC (50)
Rintatolimod Colorectal Cancer	Roswell Park Cancer Institute	P2	CCC (50)
Shr-8068 Colorectal Cancer	Fudan University	P2	CCC (50)
t3011 Colorectal Cancer	West China Hospital	P1/2	CCC (50)
Tisleizumab Colorectal Cancer	Tao Zhang	P2	CCC (50)
Trastuzumab Emtansine Colorectal Cancer	Boehringer Ingelheim	P2	CCC (50)
Vactosertib Colorectal Cancer	David Wald	P2	CCC (50)
Venetoclax Colorectal Cancer	Oslo University Hospital	P2	CCC (50)
vs-7375 Colorectal Cancer	Verastem, Inc.	P2	CCC (50)
Nadravaleucel Colorectal Cancer	BOE Technology Group Co., Ltd.	P1/2	CCC (49)
Alcestobart Colorectal Cancer	BeiGene	P1/2	CCC (48)
Alectinib Colorectal Cancer	Oslo University Hospital	P2	CCC (48)
Arsenic Trioxide Colorectal Cancer	Nazarbayev University	P1/2	CCC (48)
bhb810 Colorectal Cancer	BigHat Biosciences, Inc.	P1/2	CCC (48)
Bms-936558-01 Colorectal Cancer	Bristol-Myers Squibb	P1/2	CCC (48)
Cbp-1019 Colorectal Cancer	Coherent Biopharma (Hefei) Co., Ltd.	P1/2	CCC (48)
Crisaborole Colorectal Cancer	Sun Yat-sen University	P2	CCC (48)
Daraxonrasib Colorectal Cancer	Revolution Medicines, Inc.	P1/2	CCC (48)
Denosumab Colorectal Cancer	Redx Pharma Ltd	P2	CCC (48)
eik1005 Colorectal Cancer	Eikon Therapeutics	P1/2	CCC (48)
Eli-002 7P Colorectal Cancer	Elicio Therapeutics	P1/2	CCC (48)
Elironrasib Colorectal Cancer	Revolution Medicines, Inc.	P1/2	CCC (48)

Showing 201 to 250 of 714 assets

PreviousPage 5 of 15Next